Last year, Medtronic PLC generated 7.50B USD for its biggest-performing segment, Cardiac Rhythm & Heart Failure. The Rest of World made the largest contribution, accounting for 18.12B USD last year. For the latest quarter, Medtronic PLC reported the revenue of 2.11B USD for the period ending 2026-04-24, which came from the top-performing segment, Cardiac Rhythm & Heart Failure. Rest of World contributed the highest revenue, at 4.90B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Cardiac Rhythm & Heart Failure

Surgical & Endoscopy

Cranial & Spinal Technologies

Coronary & Peripheral Vascular

Specialty Therapies

Structural Heart & Aortic

Neuromodulation

Patient Monitoring & Respiratory Interventions

Other

Other adjustments

Coronary & Peripheral Vascular

Brain Therapies

Spine

Pain Therapies

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Cardiac Rhythm & Heart Failure

7.50B(22.57%)

6.39B(20.77%)

6.00B(20.07%)

5.78B(19.31%)

5.85B(19.94%)

5.58B(20.16%)

5.14B(19.37%)

5.85B(20.77%)

Surgical & Endoscopy

6.76B(20.34%)

6.50B(21.11%)

6.51B(21.78%)

6.15B(20.54%)

6.54B(22.30%)

5.44B(19.63%)

5.51B(20.77%)

5.75B(20.43%)

Cranial & Spinal Technologies

5.22B(15.70%)

4.97B(16.16%)

4.76B(15.92%)

4.45B(14.86%)

4.46B(15.18%)

4.29B(15.48%)

--(--)

Coronary & Peripheral Vascular

3.82B(11.48%)

--(--)

Specialty Therapies

3.00B(9.01%)

2.94B(9.55%)

2.90B(9.72%)

2.81B(9.40%)

2.59B(8.83%)

2.31B(8.33%)

1.19B(4.49%)

1.64B(5.83%)

Structural Heart & Aortic

2.66B(7.99%)

3.55B(11.55%)

3.36B(11.24%)

3.36B(11.23%)

3.06B(10.41%)

2.35B(8.50%)

1.79B(6.73%)

1.93B(6.84%)

Neuromodulation

2.07B(6.22%)

1.93B(6.28%)

1.75B(5.84%)

1.69B(5.65%)

1.74B(5.91%)

1.60B(5.78%)

--(--)

Patient Monitoring & Respiratory Interventions

2.05B(6.17%)

1.91B(6.20%)

1.91B(6.39%)

1.84B(6.13%)

1.93B(6.56%)

3.30B(11.90%)

2.84B(10.70%)

2.73B(9.67%)

Other

135.00M(0.41%)

137.00M(0.45%)

221.00M(0.74%)

495.00M(1.65%)

727.00M(2.48%)

--(--)

Other adjustments

39.00M(0.12%)

-90.00M(-0.29%)

--(--)

Coronary & Peripheral Vascular

--(--)

2.54B(8.24%)

2.48B(8.29%)

3.36B(11.23%)

2.46B(8.38%)

2.83B(10.23%)

3.54B(13.34%)

3.73B(13.24%)

Brain Therapies

--(--)

2.92B(11.01%)

2.60B(9.25%)

Spine

--(--)

2.50B(9.43%)

2.65B(9.42%)

Pain Therapies

--(--)

1.11B(4.17%)

1.28B(4.56%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Rest of World

United States

Ireland

Americas

EMEA

Asia Pacific

Other Foreign

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

Rest of World

18.12B(49.82%)

16.25B(48.45%)

15.69B(48.48%)

14.76B(47.25%)

15.45B(48.76%)

14.49B(48.12%)

13.91B(48.11%)

14.27B(46.71%)

13.99B(46.72%)

12.98B(43.68%)

12.33B(42.77%)

--(--)

United States

18.10B(49.78%)

17.17B(51.20%)

16.56B(51.17%)

16.37B(52.43%)

16.14B(50.92%)

15.53B(51.55%)

14.92B(51.60%)

16.19B(53.00%)

15.88B(53.00%)

16.66B(56.09%)

16.42B(56.96%)

--(--)

Ireland

143.00M(0.39%)

116.00M(0.35%)

113.00M(0.35%)

98.00M(0.31%)

101.00M(0.32%)

100.00M(0.33%)

85.00M(0.29%)

91.00M(0.30%)

85.00M(0.28%)

69.00M(0.23%)

79.00M(0.27%)

--(--)

Americas

--(--)

12.13B(59.84%)

9.92B(58.35%)

9.76B(58.84%)

8.83B(54.55%)

EMEA

--(--)

5.06B(24.99%)

4.48B(26.36%)

4.22B(25.47%)

4.31B(26.65%)

Asia Pacific

--(--)

2.06B(10.16%)

1.78B(10.44%)

1.89B(11.37%)

2.40B(14.82%)

Other Foreign

--(--)

1.01B(5.00%)

824.00M(4.85%)

718.00M(4.33%)

644.00M(3.98%)